• Explore /
  • Poster
  • / A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC).

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC).

Abstract Video & Slides Poster

Authors

null

Ryan Sugarman

Memorial Sloan Kettering Cancer Center, New York, NY

Ryan Sugarman , Marc Botteman , Nifasha Rusibamayila , Hiep Nguyen , Daniel Lin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Symptoms, Toxicities, and Whole-Person Care

DOI

10.1200/JCO.2022.40.4_suppl.273

Abstract #

273

Poster Bd #

F1

Abstract Disclosures

Similar Posters

First Author: Kohei Shitara

First Author: Yelena Y. Janjigian

First Author: Lin Shen

First Author: Lin Shen